You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed indolent lymphoma

Showing 26 - 50 of 9,273
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

Active, not recruiting
  • Indolent B-cell Non-Hodgkin's Lymphoma
  • Anjo, Aichi, Japan
  • +29 more
Dec 10, 2021

Leukemia Trial in New York (therapeutic autologous lymphocytes, cyclophosphamide)

Active, not recruiting
  • Leukemia
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 18, 2021

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Borddeaux Cedex, France
  • +9 more
Nov 11, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

CLL/SLL, NHL, Mantle Cell Lymphoma Trial in United States (SYNCAR-001, STK-009, Cyclophosphamide)

Recruiting
  • CLL/SLL
  • +6 more
  • Duarte, California
  • +4 more
Jan 12, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (Fludarabine, Cyclophosphamide, JCAR017)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Santa Monica, California
  • +36 more
Jan 25, 2023

Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62 Injection,

Recruiting
  • Follicular Lymphoma and Marginal Zone Lymphoma
  • Recombinant Humanized Monoclonal Antibody MIL62 Injection
  • Lenalidomide
  • Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Jun 15, 2021

Non Hodgkin Lymphoma Trial in Australia, United States (Tenalisib,)

Completed
Has Results
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +11 more
Jul 20, 2021

Non-Hodgkin Lymphoma Trial in Boston (Blinatumomab)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Boston, Massachusetts
    Massachusetts general Hospital
Jan 31, 2021

Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma Trial in Chapel Hill (CAR.k.28, Fludarabine,

Recruiting
  • Mantle Cell Lymphoma
  • +5 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Nov 19, 2021

Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Aichi, Miyagi, Tokyo (Idelalisib)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Aichi, Japan
  • +2 more
Feb 24, 2021

Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma Trial in United States (NKTR-255, NKTR-255 Q21, Rituximab)

Recruiting
  • Multiple Myeloma
  • +2 more
  • Goodyear, Arizona
  • +16 more
Mar 18, 2022

Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma

Completed
Has Results
  • Follicular Lymphoma (FL/Indolent NHL)
  • +4 more
  • Huntsville, Alabama
  • +22 more
Apr 1, 2022

Lymphoma, Non-Hodgkin Trial in Beijing (Copanlisib (Aliqopa, BAY80-6946))

Completed
  • Lymphoma, Non-Hodgkin
  • Copanlisib (Aliqopa, BAY80-6946)
  • Beijing, China
    Beijing Cancer Hospital
May 17, 2021

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in United States (Idelalisib,

Completed
Has Results
  • Indolent Non-Hodgkin's Lymphoma
  • +2 more
  • Huntsville, Alabama
  • +10 more
Feb 22, 2021

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma Trial in United States (Rituximab, ALT-803)

Terminated
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
  • Rituximab
  • ALT-803
  • Minneapolis, Minnesota
  • +3 more
Feb 11, 2021

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

Active, not recruiting
  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • External Beam Radiation Therapy
  • Orbital Radiation
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Mantle Cell Lymphoma Trial (Zanubrutinib, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
Nov 22, 2022

Leukemia, Lymphoma Trial in Seattle (rituximab, fludarabine phosphate, pixantrone dimaleate)

Withdrawn
  • Leukemia
  • Lymphoma
  • rituximab
  • +2 more
  • Seattle, Washington
    Cell Therapeutics, Incorporated
Oct 14, 2020

Hematological Malignancies Trial in Beijing, Tianjin (TQB3820 tablets)

Recruiting
  • Hematological Malignancies
  • TQB3820 tablets
  • Beijing, Beijing, China
  • +1 more
Sep 18, 2021

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
May 16, 2023

Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

Recruiting
  • Marginal Zone Lymphoma
  • Obinutuzumab, lenalidomide
  • Tianjin, Tian, China
    Institute of Hematology & Blood Diseases Hospital
Apr 27, 2023

Indolent Lymphoma, Low-dose Radiotherapy Trial in Beijing (Low-dose radiotherapy)

Recruiting
  • Indolent Lymphoma
  • Low-dose Radiotherapy
  • Low-dose radiotherapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Sep 13, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022